Dr. Mark Tullman discusses results of key clinical trials presented at the 60th annual AAN meeting on currently available disease-modifying therapies for MS and the potential implications. Medscape Neurology & Neurosurgery
More studies linking the effect of antiplatelet drugs on platelet function with clinical outcomes are urgently needed, a new review of the field concludes. Heartwire
The FDA has approved the drug, which will be marketed by Novartis as Gilenya, to reduce relapses and reduce progression of disability in patients with relapsing-remitting MS. Medscape Medical News
Drs. Wayne Hening and Jacques Montplaisir discuss the impact of restless legs syndrome on quality of life and the need for accurate diagnosis and long-term management and follow-up to improve outcomes. Medscape Family Medicine